About: Lymphocyte-to-C-Reactive Protein Ratio: A Novel Predictor of Adverse Outcomes in COVID-19

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Lymphocyte-to-C-Reactive Protein Ratio: A Novel Predictor of Adverse Outcomes in COVID-19 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Lymphocyte-to-C-Reactive Protein Ratio: A Novel Predictor of Adverse Outcomes in COVID-19
Creator	Almas, Talal Fischman, David Haq, Shujaul Roomi, Sohaib Saeed, Rehan Ullah, Waqas Haas, Donald Boigon, Margot Basyal, Bikash Madara, John Tariq, Shafaq
Source	Medline; PMC
abstract	BACKGROUND: Systemic inflammation elicited by a cytokine storm is considered a hallmark of coronavirus disease 2019 (COVID-19). This study aims to assess the validity and clinical utility of the lymphocyte-to-C-reactive protein (CRP) ratio (LCR), typically used for gastric carcinoma prognostication, versus the neutrophil-to-lymphocyte ratio (NLR) for predicting in-hospital outcomes in COVID-19. METHODS: A retrospective cohort study was performed to determine the association of LCR and NLR with the need for invasive mechanical ventilation (IMV), dialysis, upgrade to an intensive care unit (ICU) and mortality. Independent t-test and multivariate logistic regression analysis were performed to calculate mean differences and adjusted odds ratios (aORs) with its 95% confidence interval (CI), respectively. RESULTS: The mean age for NLR patients was 63.6 versus 61.6, and for LCR groups, it was 62.6 versus 63.7 years, respectively. The baseline comorbidities across all groups were comparable except that the higher LCR group had female predominance. The mean NLR was significantly higher for patients who died during hospitalization (19 vs. 7, P ≤ 0.001) and those requiring IMV (12 vs. 7, P = 0.01). Compared to alive patients, a significantly lower mean LCR was observed in patients who did not survive hospitalization (1,011 vs. 632, P = 0.04). For patients with a higher NLR (> 10), the unadjusted odds of mortality (odds ratios (ORs) 11.0, 3.6 - 33.0, P < 0.0001) and need for IMV (OR 3.3, 95% CI 1.4 - 7.7, P = 0.008) were significantly higher compared to patients with lower NLR. By contrast, for patients with lower LCR (< 100), the odds of in-hospital all-cause mortality were significantly higher compared to patients with a higher LCR (OR 0.2, 0.06 - 0.47, P = 0.001). The aORs controlled for baseline comorbidities and medications mirrored the overall results, indicating a genuinely significant correlation between these biomarkers and outcomes. CONCLUSIONS: A high NLR and decreased LCR value predict higher odds of in-hospital mortality. A high LCR at presentation might indicate impending clinical deterioration and the need for IMV.
has issue date	2020-06-25(xsd:dateTime)
bibo:doi	10.14740/jocmr4227
bibo:pmid	32655735
has license	cc-by-nc
sha1sum (hex)	0ada5c748515d91d23487d2ab157b7cf830449eb
schema:url	https://doi.org/10.14740/jocmr4227
resource representing a document's title	Lymphocyte-to-C-Reactive Protein Ratio: A Novel Predictor of Adverse Outcomes in COVID-19
has PubMed Central identifier	PMC7331862
has PubMed identifier	32655735
schema:publication	J Clin Med Res
resource representing a document's body	covid:0ada5c748515d91d23487d2ab157b7cf830449eb#body_text
is schema:about of	named entity 'gastric carcinoma' named entity 'protein' named entity 'GASTRIC CARCINOMA' named entity 'SYSTEMIC INFLAMMATION' named entity 'STUDY' named entity 'NOVEL' named entity 'cytokine storm' named entity 'This' named entity 'HCQ' named entity 'carcinomas' named entity 'IRB' named entity 'coronavirus disease 2019' named entity 'COVID' named entity 'CRP' named entity 'lymphocyte' named entity 'COVID-19' named entity '1, 2' named entity 'infection' named entity 'odds ratio' named entity 'colon' named entity 'one-way analysis of variance' named entity 'COVID' named entity 'hypertension' named entity 'causal relationship' named entity 'downstream pathways' named entity 'steroids' named entity 'neutrophil' named entity 'ANOVA' named entity 'COVID' named entity 'case fatality ratio' named entity 'immunological' named entity 'COVID-19' named entity 'goodness-of-fit test' named entity 'coagulation' named entity 'interleukins' named entity 'lymphopenia' named entity 'chronic kidney disease' named entity 'steroids' named entity 'lymphocytes' named entity 'tocilizumab' named entity 'COVID' named entity 'inflammation' named entity 'serum levels' named entity '3.5' named entity 'intensive care unit' named entity 'CRP' named entity 'odds ratio' named entity 'inflammatory response' named entity 'resource allocation' named entity 'ventilator support' named entity 'EKG' named entity 'chemotherapy' named entity 'TnT' named entity 'bone marrow' named entity 'prognosis' named entity 'Mann-Whitney U test' named entity 'ventilator support' named entity '1.6' named entity 'RT-qPCR' named entity 'dialysis' named entity 'tumor' named entity 'serum ferritin' named entity 'serum' named entity 'odds ratio' named entity '3, 4' named entity 'Lymphopenia' named entity 'intensive care' named entity 'odds ratio' named entity 'SARS-CoV-2' named entity 'neutrophilia' named entity 'COVID-19'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software